SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-254153
Filing Date
2024-11-08
Accepted
2024-11-08 16:13:55
Documents
19
Period of Report
2024-11-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d632981d8k.htm   iXBRL 8-K 30768
2 EX-1.1 d632981dex11.htm EX-1.1 247652
3 EX-5.1 d632981dex51.htm EX-5.1 8805
4 EX-99.1 d632981dex991.htm EX-99.1 6991
5 EX-99.2 d632981dex992.htm EX-99.2 7314
9 GRAPHIC g632981g1108093750920.jpg GRAPHIC 2534
10 GRAPHIC g632981g1108094038492.jpg GRAPHIC 3719
  Complete submission text file 0001193125-24-254153.txt   510907

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tvtx-20241107.xsd EX-101.SCH 2850
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvtx-20241107_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvtx-20241107_pre.xml EX-101.PRE 11261
21 EXTRACTED XBRL INSTANCE DOCUMENT d632981d8k_htm.xml XML 3648
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 241440731
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)